Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Doctorglasses Chain Co.,Ltd. (300622.SZ)
Shenzhen, GD, CN
Doctorglasses Chain Co.,Ltd. engages in the retail of eyewear in China. It offers optical glasses; smart glasses; ready-to-wear glasses series, including sunglasses, reading glasses, etc.; contact lenses; soft/hard contact lenses; care solutions, and eye health peripheral products. The company provides eye examinations and fitting, wearing, and debugging, to after-sales visit. It sells its products through its store brands comprising doctor glasses, President Optical, Boojing, zèle, Concrete, and ZORRO, as well as through e-commerce and franchise channels. Doctorglasses Chain Co.,Ltd. was founded in 1993 and is headquartered in Shenzhen, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -29.39% | -31.00% | -30.67% | -46.04% | -45.25% | -44.69% | -43.09% | -29.79% | -14.95% | +137.62% | +137.62% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+13.1% ★ Q1'26: +8.3% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+10.2% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+19.6% ★ Q1'26: +23.9% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+14.7% ★ Q1'26: +15.2% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+36.4% ★ Q1'26: +39.8% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+30.4% Q1'26: +32.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.30× ★ Q1'26: 2.06× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
471.32M
est: 483.00M (-2.4%)
|
566.06M
est: 483.00M (+17.2%)
|
655.03M
est: 592.00M (+10.6%)
|
656.31M
est: 748.00M (-12.3%)
|
962.24M
est: 932.00M (+3.2%)
|
1.18B
est: 1.17B (+0.4%)
|
1.20B
est: 1.20B (0.0%)
|
1.36B
est: 1.40B (-2.7%)
|
1.60B
1.60B – 1.60B
+14.4% YoY
|
1.83B
1.78B – 1.88B
+14.4% YoY
|
1.90B
1.90B – 1.90B
+4.1% YoY
|
| EBITDA |
67.00M
est: 60.44M (+10.8%)
|
71.58M
est: 60.44M (+18.4%)
|
81.47M
est: 74.08M (+10.0%)
|
78.21M
est: 93.60M (-16.4%)
|
97.85M
est: 116.63M (-16.1%)
|
172.30M
est: 146.53M (+17.6%)
|
140.55M
est: 406.77M (-65.4%)
|
330.55M
est: 472.78M (-30.1%)
|
540.92M
540.92M – 540.92M
+14.4% YoY
|
618.71M
601.08M – 636.33M
+14.4% YoY
|
643.90M
643.90M – 643.90M
+4.1% YoY
|
| EBIT |
62.72M
est: 55.80M (+12.4%)
|
67.21M
est: 55.80M (+20.5%)
|
76.71M
est: 68.39M (+12.2%)
|
72.67M
est: 86.41M (-15.9%)
|
87.28M
est: 107.66M (-18.9%)
|
158.38M
est: 135.27M (+17.1%)
|
132.86M
est: 205.77M (-35.4%)
|
199.45M
est: 239.16M (-16.6%)
|
273.63M
273.63M – 273.63M
+14.4% YoY
|
312.98M
304.06M – 321.90M
+14.4% YoY
|
325.73M
325.73M – 325.73M
+4.1% YoY
|
| Net Income |
52.20M
est: 45.66M (+14.3%)
|
59.32M
est: 35.12M (+68.9%)
|
62.36M
est: 37.87M (+64.6%)
|
69.17M
est: 48.89M (+41.5%)
|
75.81M
est: 51.24M (+47.9%)
|
128.06M
est: 101.59M (+26.1%)
|
103.63M
est: 103.76M (-0.1%)
|
148.61M
est: 116.60M (+27.5%)
|
160.04M
160.04M – 160.04M
+37.3% YoY
|
190.90M
190.90M – 190.90M
+19.3% YoY
|
237.77M
237.77M – 237.77M
+24.6% YoY
|
| SGA |
289.86M
est: 247.67M (+17.0%)
|
344.48M
est: 247.67M (+39.1%)
|
390.04M
est: 303.56M (+28.5%)
|
368.27M
est: 383.55M (-4.0%)
|
498.69M
est: 477.90M (+4.4%)
|
564.92M
est: 600.45M (-5.9%)
|
592.02M
est: 536.87M (+10.3%)
|
311.50M
est: 623.98M (-50.1%)
|
713.92M
713.92M – 713.92M
+14.4% YoY
|
816.58M
793.31M – 839.85M
+14.4% YoY
|
849.83M
849.83M – 849.83M
+4.1% YoY
|
| EPS |
0.33
est: 0.26 (+26.7%)
|
0.49
est: 0.20 (+144.6%)
|
0.37
est: 0.22 (+71.3%)
|
0.41
est: 0.28 (+47.0%)
|
0.44
est: 0.29 (+50.5%)
|
0.74
est: 0.58 (+27.7%)
|
0.59
est: 0.45 (+30.0%)
|
0.65
est: 0.51 (+27.5%)
|
0.70
0.70 – 0.70
+37.3% YoY
|
0.84
0.84 – 0.84
+19.3% YoY
|
1.04
1.04 – 1.04
+24.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Haiwen Kang | Deputy GM & Financial Director | — | male |
| Louisa Fan | GM & Director | — | female |
| Qing Bai He | Deputy GM & Non-Independent Director | — | male |
| Qing Qiu Zheng | Deputy GM & Non-Independent Director | — | female |
| Yanwen Zhou | Deputy General Manager | — | male |
| Yong Yang | Deputy General Manager | — | male |
| Yu Feng Xu | Accounting Supervisor | — | — |
| Yunjie Ding | Deputy GM & Secretary of the Board of Directors | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300622.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
